Paul Hudson, Sanofi CEO (Eric Piermont/AFP via Getty Images)

Up­dat­ed: Hit by an­oth­er PhI­II flop, Sanofi culls breast can­cer drug — sound­ing alarm for the class

Sanofi is of­fi­cial­ly giv­ing up on its oral SERD.

The French drug­mak­er put out word Wednes­day morn­ing that it will dis­con­tin­ue the glob­al de­vel­op­ment pro­gram of am­cen­es­trant, the se­lec­tive es­tro­gen re­cep­tor de­grad­er once billed as a top late-stage prospect. Hav­ing al­ready failed a Phase II monother­a­py test ear­li­er this year, a com­bo with the drug al­so missed the bar in a sec­ond tri­al for breast can­cer, trig­ger­ing the de­ci­sion to drop the whole pro­gram.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters